Counting the Cost of Daptomycin Versus Vancomycin in Hospitalized Patients: A Cost Minimization Analysis
Jamie L. Wagner, Bruce M Jones, Kayla R. Stover, John D. Cleary, Christopher M. Bland, Katie E Schipper, Daniel B. Chastain, Katie E. Barber
Abstract
Daptomycin use for gram-positive infections has increased. This cost minimization analysis aimed to determine cost and/or time savings of daptomycin over vancomycin. The estimated hospital cost savings was US$166.41 per patient, and pharmacist time saved of almost 20 minutes per patient. Daptomycin has the potential to save both time and money.
Topics & Concepts
MedicineDaptomycinVancomycinGram-positive bacterial infectionsIntensive care medicineAntibioticsStaphylococcus aureusMicrobiologyGeneticsBiologyBacteriaAntimicrobial Resistance in StaphylococcusBacterial Identification and Susceptibility TestingInfective Endocarditis Diagnosis and Management